Clinical Trial Update: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial update describes dosing of Brentuximab Vedotin for patients with Mycosis fungoides and Sézary syndrome, with lymphomatoid papulosis listed as a …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomatoid Papulosis
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Mycosis Fungoides, Lymphomatoid Papulosis | Phase 2 | Status: RECRUITING